ROCKVILLE, MD / ACCESS Newswire / October 21, 2025 / Radiation therapy has always been the heavyweight of cancer treatment. It works, but it's a brute. ...

Core Insights - Verastem Oncology is collaborating with GenFleet Therapeutics to develop GFH375 (VS-7375) for advanced KRAS G12D mutant pancreatic ductal adenocarcinoma, aiming to provide new treatment options for patients with limited choices [1][6] - RBC Capital maintains an "Outperform" rating on Verastem's stock, currently trading at $8.32, with a price target of $13, indicating a potential increase of 62.3% [2][5] - Despite a negative price-to-earnings (P/E) ratio of -3.38 and an enterprise value to operating cash flow ratio of -3.62, the company's strong current ratio of 3.46 suggests a solid ability to meet short-term liabilities [2][3][4] Financial Metrics - The debt-to-equity ratio of Verastem stands at 2.09, indicating a higher level of debt compared to equity [4] - The ongoing study with GenFleet Therapeutics could significantly enhance Verastem's market position and financial outlook if successful [4][5] - RBC Capital's positive outlook reflects confidence in Verastem's strategic initiatives and potential breakthroughs in oncology [5][6]

Core Insights - Genmab A/S announced updated data from the Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S) in advanced endometrial cancer patients, showing a 50.0% confirmed objective response rate (ORR) at a median follow-up of one year [1][3][5] Study Results - The study involved 64 heavily pretreated patients with advanced or recurrent endometrial cancer, with 50% ORR in the 100 mg/m² cohort, including two complete responses (CRs) [5] - In the 120 mg/m² cohort, the confirmed ORR was 44.1%, with one CR observed [6] - Among responders in the 100 mg/m² cohort, 63.6% maintained their responses at the one-year follow-up [3] Ongoing Trials - Continued evaluation of Rina-S is ongoing in the Phase 2 RAINFOL-01 trial and the Phase 3 RAINFOL-03 trial, focusing on its efficacy and safety in advanced or recurrent endometrial cancer [4] Safety Profile - Common treatment emergent adverse events (TEAEs) included cytopenias and low-grade gastrointestinal events, with no signals of ocular toxicities, neuropathy, or interstitial lung disease reported [6] Market Reaction - Following the announcement, Genmab's stock price decreased by 6.57%, trading at $30.99 [7]

Radiation Therapy Advancements - Radiation therapy is rapidly evolving, surpassing common perceptions [4] - The field has progressed from two-dimensional to three-dimensional and intensity-modulated radiation therapy (IMRT), enhancing precision [17] - Online adaptive radiotherapy integrates artificial intelligence to adjust treatment plans daily, accommodating tumor movement and changes [18][20] Treatment Methodology - Radiation therapy targets cancer cell DNA, causing breaks that cancer cells struggle to repair compared to healthy cells [5][6] - Three-dimensional radiotherapy involves immobilization, simulation scans, target delineation, and treatment planning by physicists [13][16] - Online adaptive therapy involves daily CT scans and plan re-optimization, allowing for personalized treatment adjustments [21][22] Clinical Impact - Online adaptive therapy has shown success in treating rare and recurrent cancers, such as adenoid cystic carcinoma, with improved accuracy and reduced side effects [23][24] - A specific case highlights a patient with recurrent adenoid cystic carcinoma in the trachea who remained disease-free for over a year and a half with no side effects after online adaptive therapy [24] Holistic Approach - Being a radiation oncologist involves combining scientific expertise with empathy and human connection [25][26] - The treatment process emphasizes active listening, patient support, and a collaborative team approach to improve patient outcomes [26][28] - Radiation therapy offers a less harsh alternative to surgery and chemotherapy, working quietly and powerfully [28][29]

Core Points - AIM ImmunoTech Inc. will participate in the 2025 Maxim Growth Summit on October 22-23, 2025, in New York, NY, which focuses on industry trends and advancements [1] - Management will be available for in-person one-on-one meetings with registered investors during the conference [2] - AIM ImmunoTech is an immuno-pharma company developing therapeutics for cancers, immune disorders, and viral diseases, with its lead product being Ampligen, currently in Phase 2 clinical trials for metastatic pancreatic cancer in collaboration with AstraZeneca [4] Company Information - AIM ImmunoTech Inc. specializes in research and development of therapeutics targeting multiple diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist [4] - AIM ImmunoTech is focused on broad-spectrum activity in clinical trials, particularly in combination therapies for cancer treatment [4] Event Information - The Maxim Growth Summit is organized by Maxim Group LLC, a full-service investment banking and wealth management firm based in New York [3] - The summit will feature industry leaders and innovators discussing the latest trends across various sectors [1] - For more details on the summit agenda and AIM's presentation, interested parties can visit the respective websites [2]

Summit Therapeutics ESMO Update & Q3 2025 Earnings Call October 20, 2025 8:00am ET Forward Looking Statement Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company's product candidates, entry into and actions related to the Company's partnership with Akeso Inc., the Company's anticipated spending and cash runway, the therapeutic potential of the Company's product ...

Core Insights - Johnson & Johnson announced promising results from the Phase 1b/2 OrigAMI-4 study, which evaluated the efficacy and safety of subcutaneous amivantamab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after prior treatments [1][5][6] Study Results - The study reported an overall response rate of 45% in patients with HPV-unrelated R/M HNSCC, with a median time to first response of 6.4 weeks and a median duration of response of 7.2 months [3][4] - Tumor shrinkage was observed in 82% of patients after 8.3 months of follow-up, with a median progression-free survival of 6.8 months [3][4] - The safety profile of subcutaneous amivantamab was consistent with previous studies, with common adverse events including fatigue (31%), hypoalbuminemia (31%), and stomatitis (23%) [4][5] Treatment Context - Patients with R/M HNSCC have limited treatment options and poor outcomes after disease progression on PD-1 or PD-L1 inhibitors and platinum-based chemotherapy, with response rates typically ranging from 10% to 24% [2] - RYBREVANT, the bispecific antibody targeting EGFR and MET, is positioned as a potential treatment option for these patients, highlighting the role of EGFR and MET as key tumor drivers [2][4] Future Directions - Based on the positive results from the OrigAMI-4 study, Johnson & Johnson is initiating the Phase 3 OrigAMI-5 study to further evaluate subcutaneous amivantamab in combination with pembrolizumab and carboplatin [5][6] - The findings support the broader potential of RYBREVANT-based therapies across multiple solid tumors, including non-small cell lung cancer and colorectal cancer [4][6]

Core Insights - Pfizer Inc. announced updated follow-up results from the Phase 2 PHAROS trial for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in treating adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation [1] Group 1 - In treatment-naïve patients, the median overall survival (OS) was reported at 47.6 months with a 95% confidence interval of 31.3 months, not estimable after a median follow-up of 52.3 months [1]

Core Insights - Regeneron Pharmaceuticals announced new data from the Phase 3 C-POST trial for Libtayo (cemiplimab), focusing on a patient-centric every 6-week dosing regimen for high-risk cutaneous squamous cell carcinoma (CSCC) [1][2] Group 1: Clinical Data and Trial Results - The C-POST trial data will be presented at the ESMO 2025 Meeting, highlighting the efficacy and safety of Libtayo as an adjuvant treatment for CSCC [1][2] - Patients in the trial initially received 350 mg of Libtayo every 3 weeks for 12 weeks, with most switching to every 6-week dosing thereafter, while the safety profile remained consistent with previous findings [2] Group 2: Regulatory and Approval Status - The new data supports the FDA approval of Libtayo as the first immunotherapy for adjuvant treatment of adult patients with high-risk CSCC following surgery and radiation [2] Group 3: Company Overview and Pipeline - Regeneron is focused on developing therapies for over 30 types of solid tumors and blood cancers, with nearly half of its pipeline dedicated to oncology assets [6][26] - Libtayo is a fully human monoclonal antibody targeting the PD-1 immune checkpoint, approved in over 30 countries for various indications, including advanced CSCC and non-small cell lung cancer [8][9]

Core Insights - Cellectar Biosciences presented positive preclinical data for CLR 225, an actinium-based radio conjugate, at the AACR Special Conference on Pancreatic Cancer Research, indicating its potential to inhibit tumor growth and improve survival in pancreatic cancer models [1][2] Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on developing drugs for cancer treatment, leveraging its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform [6][7] Product Development - CLR 225 has completed IND-enabling studies and is positioned to advance into Phase 1 studies, demonstrating robust anti-tumor activity and selective biodistribution in preclinical models [1][3] - The studies involved three pancreatic cancer xenograft models (PANC-1, MIA PaCa-2, and BxPC-3), showing meaningful inhibition of tumor growth and potential survival benefits [2][3] Mechanism of Action - CLR 225 targets lipid rafts to deliver treatment directly to tumor cells, addressing the dense extracellular matrix characteristic of pancreatic cancer, which is a significant barrier to effective treatment [2][5] Market Context - Pancreatic ductal adenocarcinoma (PDAC) is a severe disease with less than 10% five-year survival rate, accounting for approximately 90% of pancreatic cancer cases in the U.S. [4]